LMF ACQUISITION OPPORTUNITIES INC

NASDAQ: ICU (SeaStar Medical Holding Corpora)

Kemas kini terakhir: 29 Jul, 7:24PM

0.716

-0.04 (-5.73%)

Penutupan Terdahulu 0.759
Buka 0.760
Jumlah Dagangan 1,536,998
Purata Dagangan (3B) 7,308,577
Modal Pasaran 16,160,068
Harga / Jualan (P/S) 9.48
Harga / Buku (P/B) 31.04
Julat 52 Minggu
0.305 (-57%) — 9.10 (1171%)
Tarikh Pendapatan 11 Aug 2025 - 15 Aug 2025
Margin Operasi (TTM) -1,304.44%
EPS Cair (TTM) -2.34
Jumlah Hutang/Ekuiti (D/E MRQ) 64.25%
Nisbah Semasa (MRQ) 0.960
Aliran Tunai Operasi (OCF TTM) -15.17 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -11.89 M
Pulangan Atas Aset (ROA TTM) -144.37%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menurun
Biotechnology (Global) Bercampur Menurun
Stok SeaStar Medical Holding Corpora Bercampur Bercampur

AISkor Stockmoo

0.8
Konsensus Penganalisis NA
Aktiviti Orang Dalam NA
Volatiliti Harga 0.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 2.0
Purata 0.83

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
ICU 16 M - - 31.04
CNTA 2 B - - 5.82
GPCR 938 M - - 1.14
DNTH 683 M - - 2.08
ZBIO 612 M - - 2.18
ORKA 522 M - - -

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 1.31%
% Dimiliki oleh Institusi 5.23%

Pemilikan

Nama Tarikh Syer Dipegang
Tyche Wealth Partners Llc 30 Jun 2025 37,700
Trinity Financial Advisors Llc 30 Jun 2025 15,000
Great Valley Advisor Group, Inc. 31 Mar 2025 10,000

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
07 Aug 2025 Pengumuman SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025
06 Aug 2025 Pengumuman SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)
31 Jul 2025 Pengumuman SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
22 Jul 2025 Pengumuman SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients
16 Jul 2025 Pengumuman SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry
10 Jul 2025 Pengumuman SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08 Jul 2025 Pengumuman SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)
02 Jul 2025 Pengumuman SeaStar Medical Announces Positive Nasdaq Listing Determination
25 Jun 2025 Pengumuman SeaStar Medical Reports Update on Nasdaq Listing Status
24 Jun 2025 Pengumuman SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy
20 Jun 2025 Pengumuman SeaStar Medical Announces Pricing of Up to $8 Million Public Offering
11 Jun 2025 Pengumuman AREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical’s SCD Therapy to Advance Breakthrough Burn and Sepsis Research
28 May 2025 Pengumuman SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
14 May 2025 Pengumuman SeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business Updates
13 May 2025 Pengumuman SeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury
Papar semua
0.9760.9760.8140.8140.6520.6520.4900.4900.3280.328Jul 30Jul 30Jul 31Jul 31Aug 1Aug 1Aug 4Aug 4Aug 5Aug 5Aug 6Aug 6Aug 7Aug 7Aug 8Aug 8

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.1000.1000.0500.050-0.000-0.000-0.050-0.050-0.100-0.100MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda